UH Zaveri Limited, a company listed on the Bombay Stock Exchange (BSE: 541338), has announced the resignation of its Company Secretary and Compliance Officer, Ms. Surbhi Mathur. The resignation, effective October 1, 2025, was disclosed by the company in compliance with regulatory requirements.

Resignation Details

Ms. Mathur, who held the position of Company Secretary and Compliance Officer (ACS 61917), submitted her resignation letter to the Board of Directors on October 1, 2025. In her letter, she cited personal reasons for her decision to step down from her role.

Regulatory Compliance

UH Zaveri Limited promptly informed the BSE about this change in key managerial personnel, adhering to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also complied with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, by providing detailed disclosures about the resignation.

Management's Response

Mr. Hitesh Mahendrakumar Shah, the Managing Director of UH Zaveri Limited, signed the official communication to the BSE. The company acknowledged Ms. Mathur's contribution and has initiated the process for the necessary regulatory filings, including those with the Registrar of Companies.

Surbhi Mathur's Farewell

In her resignation letter, Ms. Mathur expressed her gratitude to the Board of Directors and the management for their support during her tenure. She described her time with the company as a valuable learning experience and an honor. Ms. Mathur also extended her wishes for the company's continued success in its future endeavors.

The resignation of a key managerial person like the Company Secretary and Compliance Officer is a significant event for any listed company. UH Zaveri Limited will likely be looking to fill this crucial position to ensure continued compliance with regulatory requirements and smooth corporate governance.

UH Zaveri Limited has unveiled the terms of its upcoming rights issue, aiming to raise up to ₹20.39 crore through the offering of new equity shares. The company's board of directors approved the issuance details in a meeting held on September 22, 2025, following the in-principle approval received from BSE Limited on July 31, 2025.

Rights Issue Details

The rights issue offers existing shareholders the opportunity to purchase additional shares in the company at a predetermined price. Key details of the issue include:

• Issue Size: Up to 2,03,88,000 fully paid-up equity shares
• Issue Price: ₹10 per share
• Rights Entitlement Ratio: 2:1 (Two new shares for every one share held)
• Record Date: October 3, 2025
• Issue Opening Date: October 30, 2025
• Issue Closing Date: November 10, 2025

Financial Impact

The rights issue is set to have a significant impact on UH Zaveri's share structure:

*Assuming full subscription

Issue Schedule and Process

The company has outlined the following schedule for the rights issue:

• Last Date for Credit of Rights Entitlements: October 27, 2025
• Last Date for On-Market Renunciation: November 4, 2025

Shareholders will be able to trade their rights entitlements on the stock exchange during this period. The International Securities Identification Number (ISIN) for the dematerialized Rights Entitlement is INE556Z20010.

Management Statement

Hitesh Mahendrakumar Shah, Managing Director of UH Zaveri Limited, signed off on the official communication to the BSE, detailing the outcome of the board meeting and the terms of the rights issue.

Investor Considerations

This rights issue presents an opportunity for existing shareholders to increase their stake in the company at a predetermined price. However, investors should carefully review the Letter of Offer, which contains detailed terms and conditions of the issue, before making any investment decisions.

The success of this rights issue could significantly bolster UH Zaveri's financial position, potentially providing the company with additional capital for future growth initiatives or debt reduction, depending on the stated use of proceeds in the offer document.

As always, investors are advised to conduct their own research and consult with financial advisors before participating in any securities offering.